This year’s Super Bowl is shaping up to be weirdly crowded with drug ads. Novo Nordisk, Lilly, Novartis, Hims & Hers—they’re all lining up to drop millions during the game. For an industry that has spent decades avoiding big cultural events in favor of the news and daytime TV, that alone should tell you something is wrong.
For years, the pharma media playbook was built on a simple truth: prescription drugs aren’t impulse buys, and you don’t decide on a treatment plan during a massive party. The Super Bowl doesn’t change that. It just makes it a lot more expensive to ignore.
So why is this a terrible idea?
You’re Talking to the Wrong People
The Super Bowl audience is huge, but it’s also completely scattershot. You’re hitting every age, every health status, and every level of medical need imaginable. Most of those viewers are not patients for your condition—and an even smaller fraction are actually looking for treatment.
There’s a reason pharma companies used to live on news programs and daytime TV: that’s where you find older viewers, people managing chronic conditions, and the caregivers who help them. The Super Bowl delivers pop-culture buzz, not medical relevance.
Reaching 100 million people when only 3% of them are even remotely in your market isn’t efficient. It’s a vanity play.
No One Can Hear You Over the Noise
Let’s be honest about how people watch the Super Bowl. They’re with friends, they’re eating and drinking, they’re yelling at the screen, and they’re scrolling through their phones.
That is a terrible place to have a conversation about a complex medical treatment. All that critical risk information? Tuned out. What specific condition does it treat? A blur. The brand name? Forgotten by the next play.
Pharma ads are trying to be funny, not because the industry suddenly got a sense of humor, but because a joke is the only way to survive in an environment where nobody wants to think about being sick. You might get some chatter on social media, but you won’t get patient understanding or a conversation with a doctor.
“Awareness” Isn’t the Problem You Think It Is
The go-to excuse for this kind of spending is always “driving awareness.” But awareness is almost never the real hurdle.
Patients don’t avoid a treatment because they’ve never heard of the brand. They avoid it because it’s too expensive, they’re worried about side effects, their insurance company makes it impossible to get, or their doctor isn’t convinced it’s the right move.
A $7 million commercial does absolutely nothing to fix any of that. It just flashes a brand name when people are least likely to do anything about it.
Pharma Is Just Following the Telehealth Hype
It’s no accident that companies like Hims & Hers and Ro are all over the Super Bowl. Their entire business is built on consumer-friendly impulse clicks, not nuanced clinical decisions.
When traditional pharma brands copy that strategy, they’re taking a playbook from the tech world and trying to apply it to a highly regulated, high-stakes medical field. It doesn’t fit. You aren’t selling sneakers or a streaming service. These are serious medications, and they shouldn’t be sold on a moment’s hype.
The ROI Math Simply Isn’t There
Good luck proving a Super Bowl ad led to a meaningful lift in prescriptions. Any sales bump can be explained away by a dozen other things, from seasonal trends to what your competitors are doing.
What you can measure is the opportunity cost. That same budget could have funded a year of sustained, targeted education in places where patients are actually researching their health—and where doctors are actually open to learning.
Instead, the industry is choosing a one-night spectacle and trying to pass it off as a strategy.
What This Spending Really Signals Is Insecurity
A Super Bowl ad doesn’t project confidence. It projects desperation.
It says you’re chasing cultural relevance because you don’t know how to prove your actual value. It says you care more about getting a round of applause in the boardroom and a write-up in the ad trades than you do about reaching the right patient.
Pharma doesn’t need to be louder. It needs to be clearer, smarter, and more attuned to how people actually make decisions about their health.
The Big Game delivers a lot of eyeballs. But for a drug company, it mostly delivers a lot of noise—and a very, very large bill.

